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Abstract
Background: It has been proposed that maternal folic-acid supplement use may alter the
DNA-methylation patterns of the offspring during the in-utero period, which could influ-
ence development and later-life health outcomes. Evidence from human studies sug-
gests a role for prenatal folate levels in influencing DNA methylation in early life, but this
has not been extended to consider persistent effects into adulthood.
Methods: To better elucidate the long-term impact of maternal folic acid in pregnancy on
DNA methylation in offspring, we carried out an epigenome-wide association study
(EWAS) nested within the Aberdeen Folic Acid Supplementation Trial (AFAST—a trial of
two different doses: 0.2 and 5mg, folic acid vs placebo). Offspring of the AFAST partici-
pants were recruited at a mean age of 47 years and saliva samples were profiled on the
Illumina Infinium Human Methylation450 array. Both single-site and differentially methy-
lated region analyses were performed.
Results: We found an association at cg09112514 (p¼4.0310–9), a CpG located in the 5’
untranslated region of PDGFRA, in the main analysis comparing the intervention arms
[low- (0.2mg) and high-dose (5mg) folic acid combined (N¼43)] vs placebo (N¼43).
Furthermore, a dose–response reduction in methylation at this site was identified in rela-
tion to the intervention. In the regional approach, we identified 46 regions of the genome
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that were differentially methylated in response to the intervention (Sidak p-value <0.05),
including HLA-DPB2, HLA-DPB1, PAX8 and VTRNA2–1. Whereas cg09112514 did not rep-
licate in an independent EWAS of maternal plasma folate, there was suggested replica-
tion of differential methylation in PAX8.
Conclusions: The results of this study suggest that maternal folic-acid supplement use is
associated with changes in the DNA methylation of the offspring that persist for many
years after exposure in utero. These methylation changes are located in genes implicated
in embryonic development, immune response and cellular proliferation. Further work to
investigate whether these epigenetic changes translate into detectable phenotypic differ-
ences is required.
Key words: epigenetic, AFAST, randomized–controlled trial, longitudinal, epigenome-wide association study, DNA
methylation
Introduction
Folate is an essential micronutrient that plays an important
role in fetal development,1 with the potential for lifelong con-
sequences.2 It is a key player in one-carbon metabolism that
is closely linked to the provision of methyl groups for the
methylation of DNA3—an epigenetic process that is crucial in
early development.4 Therefore, it has been proposed that ma-
ternal folic acid may alter the methylation patterns of the off-
spring during the in-utero period, which could impact health
outcomes in later life. This was demonstrated in the Agouti
mouse model, where methyl donor supplements (including
folate) given to pregnant dams resulted in increased DNA
methylation in the offspring at the Agouti allele, which had
phenotypic consequences of shifting offspring coat colour
and reducing the risk of obesity and tumorigenesis.5
Evidence from human studies suggests a role for prenatal
folate levels in influencing DNA methylation in neonates and
children,6–9 but this has not been extended to consider the per-
sistent effects of such exposures into adulthood. To examine
effects in adults, studies with long-term follow-up are
required. Furthermore, observational studies investigating the
impact of nutritional exposures on the epigenome are often
confounded, e.g. by other highly correlated macro/micronu-
trients or socio-economic factors not adequately captured in
these previous studies. The strongest evidence relating prenatal
nutrition to offspring methylation derives from intervention
studies (randomized–controlled trials or natural experiments).
In these studies, large differences in nutritional status occur in
the study population (largely) at random and are therefore un-
likely to be associated with confounding factors.7,10,11
To better elucidate the long-term impact of maternal folic
acid in pregnancy on DNA methylation in the offspring, we
carried out an epigenome-wide association study (EWAS)
nested within the Aberdeen Folic Acid Supplementation
Trial (AFAST). AFAST was a randomized–controlled trial of
two different doses of folic acid (0.2 or 5 mg per day vs pla-
cebo) starting at booking for antenatal care at <30 weeks’
gestation that was performed in the late 1960s.12–14
Offspring of women who participated in AFAST, born dur-
ing the trial, were identified and invited to participate in the
present study at a mean age of 47 years. Their saliva samples
were obtained for DNA-methylation profiling.
Key Messages
• We investigated the impact of a folic-acid supplementation trial that enrolled pregnant women in the late 1960s on
long-term epigenetic changes in their offspring by assessing differences in DNA-methylation levels of their offspring
at a mean age of 47 years.
• In saliva samples obtained from the offspring 47 years after the trial was conducted, we identified 45 regions of the
genome that were differentially methylated in response to the intervention.
• The results of the study suggest that maternal folic-acid supplement use is associated with changes in DNA methyla-
tion that persist for many years after in-utero exposure, but further work is needed to investigate whether these epi-
genetic changes translate into detectable phenotypic differences.
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Methods
Parent study
Study design
AFAST has been described in detail elsewhere.12–14 Briefly,
from June 1966 to June 1967, 3187 potentially eligible
women (women booking for antenatal care at <30 weeks’
gestation who were resident in Aberdeen, UK) were invited
to participate in a trial to examine the effects of folic-acid
supplement use on pregnancy outcomes. Any woman for
whom folic acid had been prescribed previously was
excluded from the study.13 In all, 2928 women were
randomized by alternate allocation to receive either 0.2 mg
folic acid/day (n¼ 466, 15.6%), 5 mg folic acid/day
(n¼ 485, 16.6%) or a placebo (n¼1977, 67.5%). Trial
compliance was assessed by self-report and by measurement
of folate status. In the placebo group, 1.9% reported that
they had not taken their tablets regularly, compared with
1.7% in the group taking 0.2mg folic acid and 3.2% in the
group taking 5 mg. Prior to allocation, serum folate concen-
trations were similar in the three groups and a dose–response
relationship was seen after allocation until the post-partum
period, indicating that the tablets were regularly taken from
the time of recruitment (mean gestational age at book-
ing¼ 17 weeks) until the end of pregnancy (mean gestational
age at delivery¼ 40 weeks).14 Among 2093 parous women,
the incidence of a positive history of congenital malforma-
tion in a previous pregnancy was 2%.13
Baseline data collection
At the booking visit, the age of the mother, her gestation,
parity, weight and blood pressure were recorded. The oc-
cupations of husbands/partners recorded on the study form
at the time of delivery were used to determine the social
class of the women based on the Classification of
Occupations 1966.15 The trial database was linked to the
Aberdeen Maternity and Neonatal Databank16 to add fur-
ther demographic information on maternal smoking and
height of mother. Additional information on mothers’
weight and blood pressure at booking were obtained from
the original obstetric records. Serum folate was measured
as previously described14 for 99.7% of women at the ante-
natal booking visit, 82.8% at approximately 30 weeks’
gestation, 37.2% at 36 weeks’ gestation and 63.4% in the
postpartum period.
Offspring study
Identification and recruitment of participants
Data from AFAST are archived within the Aberdeen
Maternity and Neonatal Databank records held by the
Institute of Applied Health Sciences, University of
Aberdeen (http://www.abdn.ac.uk/iahs/research/obsgynae/
amnd/index.php). For this study, the ‘affected’ offspring of
trial participants (i.e. the children born during the mothers’
participation in the trial) were traced using the Community
Health Index (CHI) and those living in the Grampian area
were approached for participation by mail. Multiple births
were excluded. A total of 692 offspring were invited to
participate (Supplementary Figure 1, available as
Supplementary data at IJE online) and sent an information
leaflet and consent form.
Follow-up data collection
Participants who consented to participate (N¼265,
Supplementary Figure 1, available as Supplementary data
at IJE online) were mailed a short questionnaire to collect
information on sex, age, self-reported height and weight,
education, ethnicity, their health (e.g. current medications
and health conditions) and current and past smoking status
and alcohol intake. A saliva sample collection kit
(Oragene, DNA Genetek, Kanata, Ontario, Canada) was
provided and participants were asked to collect a saliva
sample and return it through the post; 197 participants re-
turned a saliva sample and 196 completed a questionnaire,
representing a response rate of 28% (197/692).
The original trial treatment status of the study partici-
pant’s mother and other relevant trial data were provided
by the Aberdeen Maternity and Neonatal Databank and
linked to the offspring data. The linked anonymized data
were given to researchers for analysis.
DNA methylation
Of the 196 individuals who returned a saliva sample and
questionnaire, 180 individuals had DNA extracted from
saliva that passed quality control (QC). Of these, 170 were
female whereas only 10 were male. To minimize sex ef-
fects, we restricted profiling to females only and over-
sampled based on intervention status (111 individuals: 66
placebo, 21 low-dose folic acid, 24 high-dose folic acid).
Genome-wide DNA-methylation profiling was performed
on samples from 111 individuals using the Illumina
Infinium HumanMethylation 450 array,17 run as described
previously.18
Details of sampling handling and DNA-methylation
profiling are outlined in the Supplementary Material, avail-
able as Supplementary data at IJE online. For this analysis,
investigating the effect of intervention on methylation, we
included 43 placebo and 43 intervention (20 low-dose and
23 high-dose) individuals to obtain a 1:1 placebo:interven-
tion selection and reduce the effects of batch
(Supplementary Material and Figure 1, available as
Supplementary data at IJE online).
International Journal of Epidemiology, 2018, Vol. 0, No. 0 3
Downloaded from https://academic.oup.com/ije/advance-article-abstract/doi/10.1093/ije/dyy032/4931210
by University of Aberdeen user
on 22 March 2018
Ethics approval
Ethics approval was given by the NRES Committee South
West–Central Bristol REC. Approval to obtain addresses
of the offspring through the CHI was obtained from the
Caldicott Guardian, the Medical Director of NHS
Grampian. This study was conducted in accordance with
the Research Governance Framework for Health and
Social Care and Good Clinical Practice and under the
sponsorship of the University of Bristol. All samples were
used and stored in accordance with the UK Human Tissue
Act 2004.
Statistical analysis
We first aimed to assess whether the baseline characteris-
tics of the subset of individuals included in our analysis ap-
peared to be equally distributed with regard to a number
of maternal and offspring variables outlined earlier.
Continuous baseline demographic characteristics across
the three treatment groups were summarized as means and
standard deviations, and tested for overall trend using one-
way analysis of variance (ANOVA). Categorical baseline
variables were summarized as percentages and numbers in
each of the three treatment groups and an overall trend
was tested by using the chi-squared test for trend.
EWAS
We next conducted an EWAS to investigate the long-term
impact of the randomized folic-acid supplement-use inter-
vention on offspring methylation in adulthood by evaluat-
ing the association between DNA methylation (normalized
b value at 470 617 CpG sites on the array) and folic-acid
supplement use.
We first combined both the 0.2- and 5-mg treatment
groups to form a ‘folic acid supplement use’ group and car-
ried out linear regression models to test the associations be-
tween the normalized b values at each CpG site as the
dependent variable and folic-acid supplement use as the in-
dependent variable. Secondary analysis was then per-
formed to determine associations between low-dose
supplement use vs placebo, high-dose supplement use vs
placebo and an ordinal model of high dose, low dose and
placebo.
We adjusted for multiple testing using false discovery
rate correction (FDR) and also investigated CpGs with a
p-value <110–5. These analyses were adjusted for
methylation array batch and also adjusted for gestational
age at booking and age of the offspring at the time of
data and sample collection in the main analysis (folic-acid
supplement use vs placebo), given findings of a difference
in these covariates between the treatment groups. Ten
surrogate variables were generated using the ‘SVA’ pack-
age in R and included in models to adjust for technical
batch and cell-type mixture19 given the absence of meas-
ured cell types in these samples. EWAS were performed
using the ‘CpGassoc’ package20 implemented in R,
which is designed to perform flexible analyses of methyla-
tion array data and to test for an association between
methylation at CpG sites across the genome and pheno-
types of interest, adjusting for relevant covariates.
Sites were annotated using the information provided by
Illumina.9
Regional approach
Adjacent probes on the HM450 array are often highly cor-
related and differentially methylated regions (DMRs) may
be more biologically important than individual CpGs.
Therefore, as well as our single-site (CpG) analysis, we
also assessed differential methylation across larger regions
of the genome in response to the intervention. For this, we
used ‘Comb-P’ to identify regions enriched for low p-val-
ues, corrected for auto-correlation with neighbouring
CpGs within 500 base pairs using the Stouffer-Liptak
method and adjusted for multiple testing using the Sidak
correction.21
Functional analysis
To explore the function of any identified DMRs, we used
the missMethyl R package22 to test for enrichment for
any gene ontology (GO) classification terms or the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) path-
ways. The method applies Fisher tests, while correcting
for biases in the genomic coverage of the Illumina
Infinium HumanMethylation450 BeadChip array. All
CpGs on the array were used as background. We also
used Fisher tests to test whether CpGs within our DMRs
were enriched for CpGs within epialleles.36 Again, the
background was all CpGs on the array. P-values for all
enrichment analyses were adjusted for multiple testing
using the FDR method.
Replication
For replication, we performed a look-up of epigenome-
wide significant CpG sites from the single-site analysis in
an EWAS meta-analysis of maternal plasma folate and
DNA methylation (N¼ 1996) using summary-level data
from this study obtained through dbGAP (dbGAP
phs001059.v1.p1).9 Using these summary data from the
EWAS meta-analysis, where effect estimates, standard
errors and p-values were available for each CpG site, we
also used Comb-P to identify overlap with the DMRs ob-
tained from the EWAS in AFAST.
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Results
Baseline characteristics
The baseline characteristics of the pregnant women in the
three treatment groups were broadly comparable
(Table 1), with the exception of gestational age at booking,
where women in the high-dose (5 mg) folic-acid supple-
ment group were enrolled at a later gestation than in the
other two groups. However, this trend was not apparent in
the larger sample of pregnant women in the trial
(Supplementary Table 1, available as Supplementary data
at IJE online),14,23 indicating that this difference is likely
attributable to chance. An evaluation of baseline character-
istics showed no clear differences between the mothers
of offspring enrolled in this study compared with the
original sample (Supplementary Table 1, available as
Supplementary data at IJE online).
The characteristics of the female offspring from mothers
in the three treatment groups were also similar (Table 2),
with the exception of age at sample and data collection,
whereby offspring in the placebo group were slightly older
on average, and body mass index (BMI), which was higher
in the intervention groups. Given these differences, we
included gestational age and age at sample and data collec-
tion as covariates in subsequent models. As BMI may be a
possible outcome or mediator of the intervention and
methylation change, it was not considered as a covariate.
An evaluation of baseline characteristics showed no clear
differences between the offspring enrolled in this study
compared with the original sample in terms of their
birthweight or gestational age at delivery (Supplementary
Table 1, available as Supplementary data at IJE online), al-
though we were unable to assess differences between char-
acteristics in adulthood, which were absent for those
individuals who were not followed up.
EWAS
We next conducted an EWAS to investigate the long-term
impact of the randomized folic-acid supplement-use inter-
vention on offspring methylation in adulthood by evaluat-
ing the association between DNA methylation (normalized
b value at each of the 460 617 CpG sites on the array) and
folic-acid supplement use. We found an association at just
one CpG site, cg09112514, which withstood the FDR cor-
rection where the intervention was associated with a 0.8%
[95% confidence interval (CI)¼0.4, 1.2] reduction in
methylation at this site (Figure 1). A further 14 CpG sites
were found to surpass a less conservative p-value threshold
of 110–5 and effects were generally not attenuated with
additional adjustment for gestational age and age at
follow-up as covariates (Supplementary Table 2, available
as Supplementary data at IJE online). We observed a re-
duction in methylation at 9 of these 14 CpG sites in the
folic-acid supplement group vs placebo. Furthermore,
Table 1. Baseline characteristics of the mothers of participants in this study, collected as part of the original AFAST (1966–67)
(n¼86)
Variable Category Placebo (n¼43) Folic-acid supplement P
0.2 mg/day (n¼20) 5 mg/day (n¼23)
Categorical n (%) n (%) n (%) Chi2
Age at delivery (years) (N¼86) <20 5 (11.6) 3 (15.0) 4 (17.4)
20–24 10 (23.3) 8 (40.0) 10 (43.5)
25–29 16 (37.2) 4 (20.0) 5 (21.7)
30 12 (27.9) 5 (25.0) 4 (17.4) 0.50
Parity (N¼86) 0 16 (37.2) 5 (25.0) 11 (47.8)
1 or 2 19 (44.2) 12 (60.0) 9 (39.1)
3 8 (18.6) 3 (15.0) 3 (13.0) 0.53
Smoking in pregnancy (N¼83) No 21 (51.2) 13 (68.4) 11 (47.8)
Yes 20 (48.8) 6 (31.6) 12 (52.2) 0.36
Social class (N¼85) Non-manual 10 (23.3) 4 (20.0) 6 (27.3)
Manual 33 (76.7) 16 (80.0) 16 (72.7) 0.86
Pre-eclampsia (N¼86) No 31 (72.1) 16 (80.0) 17 (73.9)
Mild 12 (27.9) 4 (20.0) 6 (26.1) 0.80
Continuous Mean (SD) Mean (SD) Mean (SD) ANOVA
BMI in pregnancy (kg/m2) (N¼84) 23.6 (3.2) 23.3 (3.7) 23.7 (3.2) 0.92
Gestational age at booking (weeks) (N¼86) 16.4 (4.3) 16.3 (4.5) 20.2 (5.9) 0.006
Serum folate at booking (ng/ml) (N¼86) 6.5 (3.3) 6.5 (3.0) 5.9 (3.3) 0.79
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Table 2. Characteristics of participants included in this study (AFAST offspring, N¼ 86)
Variable Category Placebo (n¼43) Folic-acid supplement
0.2 mg/day (n¼20) 5 mg/day (n¼23)
Categorical n (%) n (%) n (%) Chi2
Age at follow-up (years) (N¼86) 46 6 (14.0) 14 (70.0) 6 (26.1)
47 33 (76.7) 6 (30.0) 17 (73.9)
48 4 (9.3) – – <0.001
Current smoking (N¼86) No 26 (60.5) 9 (45) 14 (60.9)
Yes 17 (39.5) 11 (55) 9 (39.1) 0.47
Education (N¼84) O-level 19 (46.3) 10 (50) 12 (52.2)
A-level/university 22 (53.7) 10 (50) 11 (47.8) 0.90
Alcohol intake Daily/weekly 19 (44.2) 12 (60.0) 12 (52.2) 0.56
Monthly 20 (46.5) 8 (40.0) 10 (43.5)
Not at all 4 (9.30) 0 (0) 1 (4.4)
Folic-acid supplements Yes 1 (2.3) 1 (5.0) 0 (0)
No 42 (97.7) 19 (95.0) 23 (100) 0.56
Current medication Yes 31 (72.1) 15 (75.0) 17 (73.9) 0.97
No 12 (27.9) 5 (25.0) 6 (26.1)
Health problems Yes 25 (58.1) 12 (60.0) 14 (60.9) 0.98
No 18 (41.9) 8 (40.0) 9 (39.1)
Continuous Mean (SD) Mean (SD) Mean (SD) ANOVA
BMI (kg/m2) (N¼85) 24.2 (3.8) 26.5 (6.4) 27.8 (7.2) 0.04
Length of gestation (weeks) (N¼86) 40.9 (1.1) 39.9 (2.6) 40.3 (1.5) 0.07
Birthweight (g) (N¼86) 3333 (506) 3093 (620) 3269 (493) 0.25
Figure 1. Manhattan plot for the EWAS of in-utero folic-acid supplement use (low and high dose combined vs placebo) (N¼ 86). Solid line¼ FDR
threshold for association to account for multiple testing; Dotted line¼Bonferroni corrected threshold for association to account for multiple testing.
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the same CpG site, cg09112514, was found to be most
strongly associated with both the low and high doses when
considered in separate models and was also strongly asso-
ciated in the ordinal model of high dose, low dose and pla-
cebo (p¼ 4.4710–7) (Supplementary Tables 3–5,
available as Supplementary data at IJE online) and illus-
trated a dose–response with regard to the intervention arm
(Figure 2).
We next investigated whether any of the CpG sites that
surpassed the p-value threshold of 110–5 were identified as
being either single-nucleotide polymorphism (SNP)-con-
founded or cross-hybridizing based on a comprehensive assess-
ment reported by Naeem et al.24 Two CpG sites, cg25455598
and cg13682325, identified in the main analysis were flagged
by this study as lower-quality probes (Supplementary Table 2,
available as Supplementary data at IJE online).
DMRs
Given the low power available in this study of just 86 indi-
viduals to identify strong site-specific signals, we con-
sidered taking a regional approach to assess DMRs of the
genome in response to the intervention. This was further
supported by the Q-Q and Volcano plots of the site-
specific EWAS analysis that showed an inflation of p-val-
ues above that expected by chance in the main analysis of
intervention vs placebo and particularly for the high dose
vs placebo model (Supplementary Figure 2, available as
Supplementary data at IJE online). In the DMR analysis,
we identified 46 DMRs with a Sidak p-value (multiple test-
ing corrected)< 0.05 in the main model (folic-acid supple-
ment use vs placebo) (Supplementary Table 6 and Figure
3a, available as Supplementary data at IJE online).
Furthermore, for the high dose vs placebo model and low
dose vs placebo model, 28 DMRs (Supplementary Table 7
and Figure 3b, available as Supplementary data at IJE on-
line) and 2 DMRs (Supplementary Figure 3c and Table 8,
available as Supplementary data at IJE online) were identi-
fied, respectively. Notable regions included HLA-DPB2
and HLA-DPB1, which had low regional p-values in all
models; PAX8, which was found to have low regional p-
values in both the main and high-dose models; and
VTRNA2–1, which was found to have the lowest regional
p-value in the high-dose model.
Functional analysis
CpGs within DMRs identified using the main model (folic-
acid supplement use vs placebo; 303 CpGs; Supplementary
Table 6, available as Supplementary data at IJE online)
were most enriched for KEGG pathways relating to cancer
and regulation of the actin cytoskeleton (FDR-adjusted p-
value for enrichment¼ 0.002) and GO terms related to kid-
ney development, although it should be noted that no GO
terms were enriched after correction for multiple testing.
Similarly, CpGs within DMRs identified using the high- and
low-dose models were not enriched for any KEGG path-
ways or GO terms after FDR correction (Supplementary
Tables 9 and 10, available as Supplementary data at IJE
online).
CpGs within DMRs identified using the main model
(303 CpGs; Supplementary Table 6, available as
Supplementary data at IJE online) were highly enriched for
CpGs within epiallelic regions (133 CpGs; Supplementary
Table 11, available as Supplementary data at IJE online):
six CpGs within DMRs were also within epiallelic regions
(Chi-Square 353.89; p¼ 3.610–10). All six CpGs were
within a DMR mapping to PAX8 (Chr2: 113992762–
113993314). CpGs within DMRs identified using the high-
dose model (high dose vs placebo; 170 CpGs;
Supplementary Table 7, available as Supplementary data
at IJE online) were also enriched for epialleles: 16 CpGs
within DMRs were within epiallelic regions (Chi-square
5131.91; p¼ 4.310–36). Six out of 16 CpGs were in a
DMR mapping to PAX8 and the remaining 10 CpGs were
in a DMR mapping to VTRNA2–1 (Chr5: 135414858–
135416614).
Replication
Using summary findings from a neonatal EWAS of mater-
nal plasma folate, we performed a look-up of cg09112514
(PDGFRA) and found that this did not replicate in that
study (p¼ 0.96). We also performed a DMR analysis of
Figure 2. Box plot for methylation at PDGFRA (cg09112514) in the differ-
ent intervention groups (N¼ 86).
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EWAS summary findings and then identified overlap be-
tween the DMRs identified in AFAST. A DMR at PAX8
with a regional p-value of 2.0810–6 in AFAST had a re-
gional p-value of 2.4610–10 in this independent replica-
tion sample (Supplementary Figure 4 and Table 12,
available as Supplementary data at IJE online).
Discussion
The results of this study, conducted within the context of a
randomized–controlled trial, suggest that maternal folic-
acid supplement use is associated with changes in DNA
methylation that persist for many years after in-utero ex-
posure. In saliva samples obtained from the offspring
47 years after the trial was conducted, an effect of folic-acid
supplement use on DNA methylation was identified at
cg09112514 (p¼ 4.0310–9), a CpG site in the 5’ UTR of
PDGFRA, in the main single-site EWAS analysis compar-
ing the intervention arms [low (0.2 mg) and high (5 mg)
dose folic acid] (N¼43) vs placebo (N¼43). Furthermore,
a dose–response reduction in methylation at this site was
identified with regard to the intervention. We also identi-
fied 46 regions of the genome that were differentially
methylated in response to folic-acid supplement use, includ-
ing HLA-DPB2, HLA-DPB1, PAX8 and VTRNA2–1.
PDGFRA encodes a platelet-derived growth factor re-
ceptor that has been linked with congenital neural tube de-
fects (NTDs) and isolated cleft palate.25 In particular,
mouse models have indicated that deregulated expression
of this gene leads to NTD formation26 and specific haplo-
types of the PDGFRA P1 promoter strongly affect rates of
NTD genesis.27,28 Furthermore, methylation in this gene
region has recently been linked with subtypes of orofacial
cleft.29 It is therefore interesting that we identified differen-
tial methylation at a site in PDGFRA in relation to
folic-acid supplement use, given the well-established link
between folate status in pregnancy and risk of such birth
defects.30–32 Although the effect size was small (0.8% re-
duction in methylation at this site in the folic-acid supple-
ment-use group), this does not preclude biological
plausibility of this methylation difference, which may have
subtle effects on health outcomes.
Differences in genome-wide DNA methylation have
been evaluated in relation to maternal folate and other
micronutrient exposures in candidate gene studies33 and
EWAS.34 However, unlike the study conducted here, most
previous studies investigating maternal folate have meas-
ured methylation only in newborn infants,34 with just one
study35 evaluating methylation at a later time point in in-
fancy. Therefore, our study is novel in investigating methy-
lation change into adulthood in relation to this prenatal
exposure.
Nevertheless, we attempted to replicate our findings in
the largest EWAS of maternal folate conducted to date
(N¼ 1996).9 We found no clear association between ma-
ternal cg09112514 and maternal plasma folate levels in
this study. This lack of replication between studies may re-
flect methylation profiling in different tissues (saliva vs
cord blood), differences in the timing of methylation as-
sessment (adults vs newborn infants), differences in the ex-
posure measure (folic-acid supplement use vs maternal
plasma folate) or other differences in the study design and
populations investigated.34 Alternatively, the lack of repli-
cation might indicate that this signal represents a false-
positive finding, given the small sample size of our study.
To combat the low power in our EWAS, we also took a
regional approach to assess DMRs of the genome in re-
sponse to the intervention. We also assessed replication of
the DMRs in the results from the previous EWAS9 and this
time found some suggested replication of differential
methylation at PAX8 in relation to maternal folate. In fur-
ther support for the robustness of the DMR findings, both
PAX8 and VTRNA2–1 are notable, as they are gene re-
gions in which deemed ‘metastable epialleles’ have previ-
ously been identified in relation to peri-conceptional
nutrition.11,36 Metastable epialleles are defined as those
that are influenced by the in-utero environment, occur sys-
temically and are highly stable over many years,11 which
are reflective of the methylation changes observed in this
study. However, whereas these previous studies highlight
the importance of the periconceptional environment for es-
tablishing methylation marks at these metastable epialleles,
in this study, the intervention was initiated at an average
gestational age of 16 weeks. Similarly, our top site in
PDGFRA is implicated in NTDs but the critical period for
folate status on risk of NTDs is thought to be periconcep-
tional. Nonetheless, our results are consistent with previ-
ous findings suggesting that environmentally induced
DNA-methylation change may not be limited to the peri-
conceptional period.37
We observed a reduction in methylation at 10 of the 15
top CpG sites in the folic-acid supplement use vs placebo
groups (Supplementary Table 2, available as Supplementary
data at IJE online) as well as a reduction in methylation at
287 of the 303 CpG sites contributing to the top DMRs in
the folic-acid supplement use vs placebo groups
(Supplementary Table 6, available as Supplementary data at
IJE online). Furthermore, there was widespread (although
low-magnitude) hypomethylation among those CpGs not
surpassing multiple testing correction in response to the
intervention (Supplementary Figure 2, available as
Supplementary data at IJE online). These findings of hypo-
methylation in relation to folic-acid exposure are consistent
with previous findings,8,9,38 despite the fact that folate is a
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methyl donor (and therefore might be anticipated to in-
crease methylation levels at these CpG sites). Nonetheless,
as was discussed previously,9 folic acid has been shown to
disturb the intracellular one-carbon metabolism by inhibit-
ing methylenetetrahydrofolate reductase (MTHFR) activity
that may decrease DNA methylation39 and so our findings
are not inconsistent with respect to known biological
pathways.
Key strengths of this study include the experimental de-
sign in which this study was nested, with random alloca-
tion, adequate concealment and evidence of good
compliance.14 In addition, given the identified role of folic-
acid supplement use in the prevention of NTDs, an RCT to
determine the long-term effects of in-utero exposure to
folic acid vs placebo would no longer be ethical. This his-
torical study therefore provides a unique opportunity to in-
vestigate the impact of folic-acid supplements in pregnancy
on long-term DNA-methylation changes in a trial setting.
It also illustrates a successful attempt of enrolling individ-
uals into a study through data-record linkage approxi-
mately 47 years after the initial trial, which allowed us to
look at long-term effects of in-utero exposure to folic acid.
Furthermore, participants included in this study were simi-
lar to the original study sample with respect to the baseline
characteristics, indicating that the randomized nature of
the intervention was preserved. This study also highlights
the value of saliva as a non-invasive sample on which to
perform DNA-methylation profiling40 and the value of
methylation profiles as a biosocial archive for historical
exposure.41
Limitations include the small sample size of this study,
which might have generated spurious associations at the
single-CpG level in the EWAS as a result of low power, al-
though the replication of DMRs in independent studies
supports the robustness of these findings. A further limita-
tion relates to the fact that this study was conducted in fe-
male offspring only and individuals residing within the
Grampian area, meaning results may not be generalizable.
As the offspring response rate was 28%, selection bias
could have played a role in our results, although an evalu-
ation of baseline characteristics revealed no clear differ-
ences between the mothers or offspring of those enrolled in
this study compared with the original sample.
Overall, the results of this study suggest that maternal
folic-acid supplement use, even after the periconceptional
period, is associated with changes in DNA methylation in the
offspring that persist for many years after in-utero exposure.
These methylation changes are located in genes implicated in
pathways related to cancer, metabolism and infection, and
therefore may mediate long-term effects of folic-acid exposure
in pregnancy.14,42,43 However, the causal relevance of these
methylation changes with regard to these developmental and
health outcomes remains to be determined. Further work to
investigate whether these epigenetic changes translate into de-
tectable phenotypic differences is required.
Supplementary data
Supplementary data are available at IJE online
Funding
This work was supported by the NIHR Bristol Biomedical Research
Centre at the University Hospitals Bristol NHS Foundation Trust
and the University of Bristol. The views expressed in this publication
are those of the authors and not necessarily those of the NHS, the
National Institute for Health Research or the Department of Health.
R.C.R., G.C.S., N.K., T.G., G.D.S. and C.L.R. work in a unit that
receives funds from the University of Bristol and the UK Medical
Research Council (MC_UU_12013/1, MC_UU_12013/2 and
MC_UU_12013/8). This work was also supported by CRUK (grant
number C18281/A19169) and the ESRC (grant number ES/
N000498/1). C.M.T. is supported by a Wellcome Trust Career Re-
entry Fellowship (grant number 104077/Z/14/Z).
Conflict of interest: None declared.
References
1. Scholl TO, Johnson WG. Folic acid: influence on the outcome of
pregnancy. Am J Clin Nutr 2000;71(Suppl 5):1295S–303.
2. Barua S, Kuizon S, Junaid MA. Folic acid supplementation in
pregnancy and implications in health and disease. J Biomed Sci
2014;21:77.
3. Anderson OS, Sant KE, Dolinoy DC. Nutrition and epigenetics:
an interplay of dietary methyl donors, one-carbon metabolism
and DNA methylation. J Nutr Biochem 2012;23:853–59.
4. Waterland RA, Michels KB. Epigenetic epidemiology of the de-
velopmental origins hypothesis. Annu Rev Nutr 2007;27:
363–88.
5. Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigen-
etics and methyl supplements affect agouti gene expression in
Avy/a mice. FASEB J 1998;12:949–57.
6. Steegers-Theunissen RP, Obermann-Borst SA, Kremer D et al.
Periconceptional maternal folic acid use of 400 microg per day is
related to increased methylation of the IGF2 gene in the very
young child. PLoS One 2009;4:e7845.
7. Cooper WN, Khulan B, Owens S et al. DNA methylation profil-
ing at imprinted loci after periconceptional micronutrient sup-
plementation in humans: results of a pilot randomized controlled
trial. FASEB J 2012;26:1782–90.
8. Amarasekera M, Martino D, Ashley S et al. Genome-wide DNA
methylation profiling identifies a folate-sensitive region of differ-
ential methylation upstream of ZFP57-imprinting regulator in
humans. FASEB J 2014;28:4068–76.
9. Joubert BR, den Dekker HT, Felix JF et al. Maternal plasma fol-
ate impacts differential DNA methylation in an epigenome-wide
meta-analysis of newborns. Nat Commun 2016;7:10577.
10. Heijmans BT, Tobi EW, Stein AD et al. Persistent epigenetic dif-
ferences associated with prenatal exposure to famine in humans.
Proc Natl Acad Sci USA 2008;105:17046–49.
International Journal of Epidemiology, 2018, Vol. 0, No. 0 9
Downloaded from https://academic.oup.com/ije/advance-article-abstract/doi/10.1093/ije/dyy032/4931210
by University of Aberdeen user
on 22 March 2018
11. Waterland RA, Kellermayer R, Laritsky E et al. Season of
conception in rural gambia affects DNA methylation at
putative human metastable epialleles. PLoS Genet 2010;6:
e1001252.
12. Hall MH, Pirani BB, Campbell D. The cause of the fall in serum
folate in normal pregnancy. Br J Obstet Gynaecol 1976;83:
132–36.
13. Hall MH. Folic acid deficiency and congenital malformation.
J Obstet Gynaecol Br Commonw 1972;79:159–61.
14. Charles DHM, Ness AR, Campbell D, Smith GD, Whitley E,
Hall MH. Folic acid supplements in pregnancy and birth out-
come: re-analysis of a large randomised controlled trial and up-
date of Cochrane review. Paediatr Perinat Epidemiol 2005;19:
112–24.
15. General Register Office. Classification of Occupations. London:
HMSO, 1966.
16. Ayorinde AA, Wilde K, Lemon J, Campbell D, Bhattacharya S.
Data resource profile: the Aberdeen Maternity and Neonatal
Databank (AMND). Int J Epidemiol 2016;45:389–94.
17. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C,
Fuks F. Evaluation of the infinium methylation 450K technol-
ogy. Epigenomics 2011;3:771–84.
18. Relton CL, Gaunt T, McArdle W et al. Data resource profile:
Accessible Resource for Integrated Epigenomic Studies (ARIES).
Int J Epidemiol 2015;44:1181–90.
19. McGregor K, Bernatsky S, Colmegna I et al. An evaluation of
methods correcting for cell-type heterogeneity in DNA methyla-
tion studies. Genome Biol 2016;17:84.
20. Barfield RT, Kilaru V, Smith AK, Conneely KN. CpGassoc: an R
function for analysis of DNA methylation microarray data.
Bioinformatics 2012;28:1280–81.
21. Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: soft-
ware for combining, analyzing, grouping and correcting spatially
correlated P-values. Bioinformatics 2012;28:2986–88.
22. Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package
for analyzing data from Illumina’s HumanMethylation450 plat-
form. Bioinformatics 2016;32:286–88.
23. Taylor CM, Atkinson C, Penfold C et al. Folic acid in pregnancy
and mortality from cancer and cardiovascular disease: further
follow-up of the Aberdeen folic acid supplementation trial.
J Epidemiol Community Health 2015;69:789–94.
24. Naeem H, Wong NC, Chatterton Z et al. Reducing the risk of false
discovery enabling identification of biologically significant genome-
wide methylation status using the HumanMethylation450 array.
BMC Genomics 2014;15:51.
25. Rattanasopha S, Tongkobpetch S, Srichomthong C, Siriwan P,
Suphapeetiporn K, Shotelersuk V. PDGFRa mutations in humans
with isolated cleft palate. Eur J Hum Genet 2012;20:1058–62.
26. Helwig U, Imai K, Schmahl W et al. Interaction between undu-
lated and patch leads to an extreme form of spina-bifida in
double-mutant mice. Nat Genet 1995;11:60–63.
27. Joosten PH, Toepoel M, Mariman EC, Van Zoelen EJ. Promoter
haplotype combinations of the platelet-derived growth factor
alpha-receptor gene predispose to human neural tube defects.
Nat Genet 2001;27:215–17.
28. Zhu H, Wicker NJ, Volcik K et al. Promoter haplotype combin-
ations for the human PDGFRA gene are associated with risk of
neural tube defects. Mol Genet Metab 2004;81:127–32.
29. Sharp GC, Ho K, Davies A et al. Distinct blood DNA methylation
profiles in subtypes of orofacial cleft. Clin Epigenetics 2017;9:63.
30. Group MVSR. Prevention of neural tube defects: results of the
Medical Research Council Vitamin Study. Lancet 1991;338:
131–37.
31. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-
tube defects by periconceptional vitamin supplementation. N
Engl J Med 1992;327:1832–35.
32. Relton CL, Wilding CS, Laffling AJ et al. Low erythrocyte folate
status and polymorphic variation in folate-related genes are asso-
ciated with risk of neural tube defect pregnancy. Mol Genet
Metab 2004;81:273–81.
33. van Mil NH, Bouwland-Both MI, Stolk L et al. Determinants of
maternal pregnancy one-carbon metabolism and newborn
human DNA methylation profiles. Reproduction 2014;148:
581–92.
34. Richmond RC, Joubert BR. Contrasting the effects of intra-
uterine smoking and one-carbon micronutrient exposures on off-
spring DNA methylation. Epigenomics 2017;9:351–67.
35. Khulan B, Cooper WN, Skinner BM et al. Periconceptional ma-
ternal micronutrient supplementation is associated with wide-
spread gender related changes in the epigenome: a study of a
unique resource in the Gambia. Hum Mol Genet 2012;21:
2086–101.
36. Silver MJ, Kessler NJ, Hennig BJ et al. Independent genomewide
screens identify the tumor suppressor VTRNA2-1 as a human
epiallele responsive to periconceptional environment. Genome
Biol 2015;16:118.
37. Tobi EW, Lumey LH, Talens RP et al. DNA methylation differ-
ences after exposure to prenatal famine are common and timing-
and sex-specific. Hum Mol Genet 2009;18:4046–53.
38. Gonseth S, Roy R, Houseman EA et al. Periconceptional folate
consumption is associated with neonatal DNA methylation
modifications in neural crest regulatory and cancer development
genes. Epigenetics 2015;10:1166–76.
39. Smith DE, Hornstra JM, Kok RM, Blom HJ, Smulders YM.
Folic acid supplementation does not reduce intracellular homo-
cysteine, and may disturb intracellular one-carbon metabolism.
Clin Chem Lab Med 2013;51:1643–50.
40. Teschendorff AE, Yang Z, Wong A et al. Correlation of
smoking-associated DNA methylation changes in buccal cells
with DNA methylation changes in epithelial cancer. JAMA
Oncol 2015;1:476–85.
41. Relton CL, Hartwig FP, Davey Smith G. From stem cells to the
law courts: DNA methylation, the forensic epigenome and the
possibility of a biosocial archive. Int J Epidemiol 2015;44:
1083–93.
42. Campbell NRC. How safe are folic acid supplements? Arch
Intern Med 1996;156:1638–44.
43. Burdge GC, Lillycrop KA. Folic acid supplementation in preg-
nancy: are there devils in the detail? Br J Nutr 2012;108:
1924–30.
10 International Journal of Epidemiology, 2018, Vol. 0, No. 0
Downloaded from https://academic.oup.com/ije/advance-article-abstract/doi/10.1093/ije/dyy032/4931210
by University of Aberdeen user
on 22 March 2018
